chiglitazar sodium + metformin

Chiglitazar sodium + metformin (often referred to in Chinese clinical registries as siglitazone sodium + metformin) is a fixed-dose combination (FDC) therapy developed by Chipscreen Biosciences for the treatment of type 2 diabetes mellitus (T2DM). Chiglitazar sodium is a novel, non-thiazolidinedione pan-peroxisome proliferator-activated receptor (PPAR) agonist that targets all three PPAR isoforms (α, γ, and δ). This pan-agonist approach is designed to provide a balanced regulation of glucose and lipid metabolism while improving insulin sensitivity. Metformin is a biguanide that primarily reduces hepatic glucose production and improves peripheral glucose uptake. The combination aims to provide synergistic glycemic control and improve patient compliance through a single, extended-release tablet formulation. Chiglitazar sodium was first approved as a monotherapy in China in 2021 under the brand name Carflogli.

Brand names

Bilessmet必利泰

Other names

siglitazone sodium + metforminchiglitazar + metforminchiglitazar sodium + metformin hydrochloridesiglitazone sodium + metformin ER